Pfizer’s Rituxan biosimilar bags FDA approval
The treatment has been approved in adult patients with non-Hodgkin’s lymphoma.
Read More
Tag: Rituxan
Rituxan hits endpoints in late-stage skin disease trial
The drug demonstrated superiority to current standard-of-care to CellCept.
Read More
Sandoz dumps US filing for biosimilar rituximab
Novartis group Sandoz has decided not to pursue US submission of a biosimilar version of Roche’s Rituxan/Mabthera, after a request from regulators for more data.
Read More
Green light for Roche/AbbVie’s chemo-free CLL treatment combo
Roche says a combination of Venclyxto and MabThera has been approved in the European Union for people with previously treated chronic lymphocytic leukaemia.
Read More
AbbVie unveils high undetectable disease rates for venetoclax/rituximab combo
AbbVie has unveiled new data showing high and durable undetectable minimal residual disease rates in patients with chronic lymphocytic leukaemia treated with venetoclax in combination with rituximab.
Read More
US nod for Venclexta/Rituxan combo
US regulators have approved a combination of AbbVie and Roche’s Venclexta in combination with Roche/Biogen’s Rituxan (rituximab) to treat chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).
Read More
US widens scope of Rituxan to include life-threatening skin condition
Roche group Genentech has received US approval for Rituxan to treat moderate to severe pemphigus vulgaris (PV), giving patients access to the first new therapy for the condition in more than 60 years.
Read More
US delay for Celltrion’s Rituxan, Herceptin biosimilars
The US Food and Drug Administration has rejected Celltrion’s submissions for biosimilars to Roche drugs Rituxan and Herceptin.
Read More
AbbVie/Roche’s venetoclax hits goals in CLL trial
A combination of AbbVie and Roche’s venetoclax and rituximab has shown a progression-free survival benefit in patients with chronic lymphocytic leukaemia (CLL).
Read More
Roche’s Gazyva fails to hit target in lymphoma trial
Roche’s new blood cancer drug Gazyva has failed to show significant improvements versus veteran therapy MabThera/Rituxan in patients with previously untreated diffuse large B-cell lymphoma, marking a setback in plans to protect sales from biosimilar competition.
Read More
- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
- Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- US study reveals interferon combinations cause lupus symptoms and affect treatment
